Welcome to our dedicated page for Health In Tech SEC filings (Ticker: HIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health In Tech, Inc. (Nasdaq: HIT) files a range of reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed, Nevada-incorporated InsurTech platform company. Its SEC filings provide detailed information on financial performance, governance, equity plans, and material corporate events related to its AI-enabled healthcare and insurance marketplace.
On this page, you can review Health In Tech’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss revenues, operating expenses, cash flows, and segment-related data for its insurance technology platform. These filings also describe risk factors, business strategy, and the company’s focus on process simplification and automation for insurers, brokers, and TPAs.
Health In Tech’s current reports on Form 8-K document specific events such as earnings announcements, investor presentations, stockholder meetings, equity incentive plan amendments, restricted stock awards tied to new initiatives and programs, and changes in executive roles. For example, 8-K filings describe the company’s annual meeting voting results, grants of restricted stock for new initiatives, and terminations or appointments of certain officers.
Investors interested in ownership and governance can use proxy materials such as the DEF 14A definitive proxy statement to understand board elections, equity plan proposals, auditor ratification, and voting structures for Class A and Class B common stock. These documents outline how Health In Tech manages compensation, board composition, and stockholder rights.
Stock Titan enhances access to these filings with AI-powered summaries that explain key points from lengthy documents, helping users quickly interpret complex sections of 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new filings for HIT appear promptly, while structured views of forms such as 8-K and proxy statements make it easier to track developments in Health In Tech’s InsurTech operations, capital structure, and governance over time.
Health In Tech, Inc. (HIT) reported an insider grant to Tim Johnson, who is the company's Chief Executive Officer, a director and a >10% owner. On 09/24/2025 Mr. Johnson was granted 80,000 restricted shares of Class A Common Stock under the Health in Tech Equity Incentive Plan at no cash price. The restricted shares vest in three equal tranches, each vesting monthly over a 12-month period tied to milestones: signing a letter of intent or MOU for an initiative, proof-of-concept or beta launch, and full commercial launch. After the grant Mr. Johnson beneficially owns 22,549,741 shares (which the form notes includes 137,495 restricted shares and 22,412,246 Class A shares); the filing excludes 9,000,000 Class B shares and 734,707 options.
Health In Tech, Inc. reported that its Compensation Committee approved new restricted stock awards for its two top executives tied to a specific new business initiative. On September 24, 2025, the company granted 80,000 shares of restricted stock to Chief Executive Officer Tim Johnson and 80,000 shares of restricted stock to Chief Financial Officer Linlin (Julia) Qian. These awards are meant to compensate them for work on a new initiative described as the “Initiative.”
Each grant is structured so that one third of the shares vest in monthly installments over 12 months starting when a letter of intent or memorandum of understanding is signed, another third vests monthly over 12 months starting when the Initiative reaches proof-of-concept or beta launch, and the final third vests monthly over 12 months starting at full commercial launch. The awards were made under the company’s existing Equity Incentive Plan and follow previously approved restricted stock award agreement terms.
LinLin Qian, who serves as Chief Financial Officer, a director and a >10% owner of Health In Tech, Inc. (HIT), received a grant of 80,000 restricted shares of Class A Common Stock on 09/24/2025 at a reported price of $0. Following the grant, the reporting person beneficially owns 8,128,555 shares, which the filing states includes 130,495 restricted shares and 7,998,060 Class A shares (the filing separately excludes 2,700,000 Class B shares and 711,510 options). The restricted shares vest in three equal tranches tied to an initiative: monthly over 12 months after a letter of intent, monthly over 12 months after proof-of-concept or beta launch, and monthly over 12 months after full commercial launch.
Health In Tech, Inc. is soliciting votes for its annual meeting and has mailed a Proxy Statement and Annual Report to holders of record as of August 6, 2025. The filing outlines meeting logistics, voting procedures (including a telephonic proxy deadline of 11:59 p.m. ET on October 2, 2025), broker voting treatment for "routine" items, and deadlines for stockholder proposals and director nomination notices for the 2026 meeting (May 13, 2026 for proposals; August 4, 2026 for contested-nomination notices under Rule 14a-19).
The statement identifies the company's executive officers and board members, describes committee charters and responsibilities (audit, compensation, nominating/governance), discloses a related-party services amounting to $940,915 through May 31, 2023, and notes corporate actions including a retroactive stock split effected June 4, 2024. Director compensation includes an $80,000 restricted stock award for non-employee directors vesting after one year. The Audit Committee reports pre-approval of Malone Bailey's 2024 services.
Health In Tech, Inc. (HIT) reporting person LinLin Qian, who serves as Chief Financial Officer, Director and a reported 10% owner, received a grant of 27,000 restricted shares of Class A Common Stock on 08/15/2025. The restricted shares were issued under the Health in Tech Equity Incentive Plan and vest based on operational milestones: 50% vest monthly over 12 months after the first specified program is launched and operational, and the remaining 50% vest monthly over 12 months after the second specified program is launched and operational. Following the transaction the reporting person beneficially owns 8,048,555 shares (which the filing states include 55,193 restricted shares and 7,993,362 Class A shares), while the filing excludes certain Class B shares and options.
Tim Johnson, the Chief Executive Officer, Director and 10% owner of Health In Tech, Inc. (HIT), was granted 34,000 restricted shares of Class A Common Stock on 08/15/2025. The shares were granted at $0 and are subject to performance-based vesting tied to the successful launch and full operation of two specified company programs: 50% vest monthly over 12 months after the first program is launched and operational, and the remaining 50% vest monthly over 12 months after the second program is launched and operational. After this grant the reporting person beneficially owns 22,469,741 shares, which the filing clarifies includes 62,193 restricted shares and 22,407,548 Class A shares and expressly excludes 9,000,000 Class B shares and 734,707 options to purchase Class A shares.
Health In Tech, Inc. (HIT) reporting person Imran Yousuf, Chief Technology Officer and Director, received a grant of 7,000 restricted Class A common shares on 08/15/2025. The restricted shares are subject to vesting tied to two separate product launches: 50% vests monthly over 12 months after the first specified program is successfully launched and operational, and the remaining 50% vests monthly over 12 months after the second specified program is successfully launched and operational. Following the grant the reporting person beneficially owns 107,000 shares (comprised of 100,000 shares and 7,000 restricted shares). The filing excludes 100,000 options to purchase Class A common stock.
Health In Tech insider Jonathan Del Lockett reported a grant of 7,000 restricted shares of Class A common stock on 08/15/2025. The restricted shares were granted under the Health in Tech Equity Incentive Plan and carry vesting conditions tied to the successful launch and full operation of two specified company programs: 50% of the restricted shares vest monthly over 12 months after the first program is launched, and the remaining 50% vest monthly over 12 months after the second program is launched. Following the reported transaction, Mr. Lockett beneficially owns 93,539 shares (including 22,105 restricted shares and 71,434 unrestricted Class A shares); the filing notes he also holds 165,085 options to purchase Class A common stock that are excluded from the ownership total.
Health In Tech, Inc. reported that its Compensation Committee approved new restricted stock awards for three senior executives tied to the development of two new programs, referred to as Program 1 and Program 2. Chief Executive Officer Tim Johnson was granted 17,000 shares for each program, Chief Financial Officer Linlin (Julia) Qian was granted 10,000 shares for Program 1 and 17,000 shares for Program 2, and Chief Technology Officer (Mo) Imran Yousuf was granted 3,500 shares for each program.
Half of each executive’s grant will vest in equal monthly installments over twelve months starting when the first of the two programs is successfully launched and fully operational in the marketplace. The remaining half will vest in equal monthly installments over twelve months starting when the other program is successfully launched and fully operational. These awards were made under the company’s Equity Incentive Plan and follow previously approved restricted stock award agreements.
Health In Tech, Inc. reported accelerating revenue and margin expansion for the six months ended June 30, 2025. Total revenues rose to $17.33 million from $10.13 million a year earlier, driven by higher fees and underwriting modeling services, producing gross profit of $11.67 million and net income of $1.13 million, up from $438,543. Cash and cash equivalents increased modestly to $8.14 million, supported in part by net IPO proceeds of $8.21 million received previously.
The balance sheet shows growth in non-current and other receivables to $3.85 million, reflecting purchases of deferred administrative surplus; accounts payable rose to $4.33 million. The company recognized a refund liability of $955,743 tied to a variable reconciliation clause with a carrier and recorded stock-based compensation expense of $1.20 million during the period. Significant customer and vendor concentrations and collection uncertainty on purchased receivables are material risks disclosed in the filing.